Private Advisor Group LLC Has $368,000 Stake in Biohaven Ltd. (NYSE:BHVN)

Private Advisor Group LLC trimmed its holdings in Biohaven Ltd. (NYSE:BHVN) by 3.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,364 shares of the company’s stock after selling 285 shares during the period. Private Advisor Group LLC’s holdings in Biohaven were worth $368,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Biohaven by 280.5% in the first quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock valued at $345,031,000 after buying an additional 4,650,702 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Biohaven by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,347,022 shares of the company’s stock valued at $183,050,000 after acquiring an additional 212,699 shares during the last quarter. Farallon Capital Management LLC increased its stake in Biohaven by 181.4% in the second quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock valued at $78,028,000 after acquiring an additional 1,449,000 shares during the last quarter. Darwin Global Management Ltd. bought a new position in Biohaven in the first quarter valued at approximately $80,776,000. Finally, Armistice Capital LLC increased its stake in Biohaven by 74.8% in the second quarter. Armistice Capital LLC now owns 1,396,968 shares of the company’s stock valued at $48,489,000 after acquiring an additional 597,705 shares during the last quarter. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Gregory Bailey bought 5,000 shares of Biohaven stock in a transaction dated Tuesday, September 24th. The stock was purchased at an average cost of $44.19 per share, with a total value of $220,950.00. Following the transaction, the director now directly owns 1,620,071 shares of the company’s stock, valued at approximately $71,590,937.49. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director John W. Childs bought 21,052 shares of Biohaven stock in a transaction dated Wednesday, October 2nd. The stock was purchased at an average cost of $47.50 per share, with a total value of $999,970.00. Following the transaction, the director now directly owns 21,052 shares of the company’s stock, valued at approximately $999,970. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gregory Bailey acquired 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 24th. The stock was acquired at an average cost of $44.19 per share, with a total value of $220,950.00. Following the completion of the acquisition, the director now owns 1,620,071 shares in the company, valued at $71,590,937.49. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 16.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Biohaven in a research note on Monday, September 16th. They set a “buy” rating and a $57.00 target price on the stock. Bank of America boosted their price objective on shares of Biohaven from $52.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. UBS Group reduced their price objective on shares of Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. Sanford C. Bernstein boosted their target price on shares of Biohaven from $55.00 to $66.00 and gave the company an “outperform” rating in a report on Tuesday, September 24th. Finally, Morgan Stanley began coverage on shares of Biohaven in a report on Wednesday, July 24th. They issued an “overweight” rating and a $58.00 target price on the stock. Thirteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $61.92.

Biohaven Price Performance

BHVN opened at $51.40 on Wednesday. Biohaven Ltd. has a fifty-two week low of $26.80 and a fifty-two week high of $62.21. The firm has a market capitalization of $4.86 billion, a PE ratio of -5.47 and a beta of 1.31. The company’s 50-day moving average is $46.04 and its 200 day moving average is $40.19.

Biohaven (NYSE:BHVN) last posted its earnings results on Thursday, August 8th. The company reported ($3.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($1.92). As a group, analysts expect that Biohaven Ltd. will post -8.81 EPS for the current year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.